Related Experiment Video
Updated: Jun 22, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
Maurício Batista Paes Landim1, Antônio Casella Filho, Antônio Carlos Palandri Chagas
1Heart Institute, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. landim@cardiol.br
Clinics (Sao Paulo, Brazil)
|June 3, 2009
Summary
Asymmetric dimethylarginine (ADMA) contributes to atherosclerosis by reducing nitric oxide. Lowering ADMA levels through therapies may combat this leading cause of heart disease.
Area of Science:
- Cardiovascular Research
- Biochemistry
- Nephrology
Background:
- Atherosclerotic coronary heart disease is a major global health concern.
- Endothelial dysfunction, characterized by reduced nitric oxide bioavailability, precedes atherosclerosis.
- Asymmetric dimethylarginine (ADMA) impairs nitric oxide formation and is linked to atherosclerosis risk factors.
Purpose of the Study:
- To review the formation and degradation pathways of ADMA.
- To discuss the role of ADMA in the atherogenic process.
- To explore potential therapeutic strategies targeting ADMA.
Main Methods:
- Literature review of basic science and clinical research.
- Analysis of ADMA's biochemical pathways (synthesis and degradation).
- Examination of ADMA's association with cardiovascular risk factors.
Main Results:
- ADMA is formed by methyltransferase enzymes and eliminated via renal excretion or dimethylarginine dimethylaminohydrolases (DDAH).
- Elevated ADMA levels are observed in conditions such as chronic renal insufficiency, dyslipidemia, hypertension, and diabetes.
- ADMA acts as a mediator of vascular effects associated with atherosclerosis risk factors.
Conclusions:
- ADMA plays a significant role in the development of atherosclerosis.
- Therapeutic interventions aimed at reducing ADMA levels or enhancing its degradation show promise.
- Further research is needed to confirm ADMA's role as a biomarker and therapeutic target in atherosclerosis.
More Related Videos
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...